FDA approves Perseris for extended-release injectable suspension to treat schizophrenia in adults

Image: FDA Building 51 in Silver Spring, Maryland which houses the Center for Drug Evaluation and Research. Photo: courtesy of The U.S. Food and Drug Administration/Wikipedia.org.